https://pubmed.ncbi.nlm.nih.gov/35061867/
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c...
Finerenone reduces kidney and cardiovascular outcome risk in patients with CKD and T2D, and risks appear consistent irrespective of HbA1c levels or insulin use.
https://pubmed.ncbi.nlm.nih.gov/34449181/?dopt=Abstract
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria,...
kidney diseasecardiovasculareventsfinerenone
https://scholarworks.indianapolis.iu.edu/items/ba16daa3-5dae-4cf1-8566-f63f032603b8
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2...
Background: Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at risk of atrial fibrillation or flutter (AFF) due to cardiac remodeling...
https://pubmed.ncbi.nlm.nih.gov/33264825/?dopt=Abstract
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded...
chronic kidney disease
https://www.nice.org.uk/guidance/ta877/chapter/4-Implementation
4 Implementation | Finerenone for treating chronic kidney disease in type 2 diabetes | Guidance |...
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults
chronic kidney disease
https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/bayer-working-on-phase-3-trials-for-finerenone-as-potential-treatment-for-heart-failure-non-diabetes-ckd/108824222
Bayer working on Phase 3 trials for Finerenone as potential treatment for heart failure,...
Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with Chronic Kidney Disease (CKD)...
https://pubmed.ncbi.nlm.nih.gov/40072066/?dopt=Abstract
Finerenone Alleviates Over-Activation of Complement C5a-C5aR1 Axis of Macrophages by Regulating G...
Diabetic nephropathy (DN), one of the most common complications of diabetes mellitus (DM), accounts for a major cause of chronic kidney disease (CKD)...
https://www.sciencedaily.com/releases/2021/08/210830100017.htm
Finerenone improves outcomes in patients with mild-to-moderate kidney disease and diabetes |...
Finerenone reduces the risk of cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease and type 2 diabetes. Diabetic kidney...
https://adisinsight.springer.com/drugsafety/803929053?error=cookies_not_supported&code=d79486b8-ac96-4bef-99a2-b25ffcc01449
Finerenone - AdisInsight
A patient [age not stated] [sex not stated] with type 2 diabetes and chronic kidney disease in a retrospective cohort received gradual combination therapy with
finerenoneadisinsight
https://tobias-lib.uni-tuebingen.de/xmlui/handle/10900/154128
Rationale and design of a randomised phase III registration trial investigating finerenone in...
https://ce.massmed.nejm.org/nejm-weekly-cme/content/finerenone-type-1-diabetes-and-chronic-kidney-disease
Finerenone in Type 1 Diabetes and Chronic Kidney Disease | MMS/NEJM Continuing Education Center
https://www.mdpi.com/2077-0383/12/19/6285
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
Nonsteroidal mineralocorticoid receptor antagonists (MRAs) present a promising therapeutic option in cardiorenal diseases, mitigating the limitations of...
mineralocorticoid receptornonsteroidalantagonistfinerenonedisease